ArticleScientific reports2025
Biofilm proficient Bacillus subtilis prevents neurodegeneration in Caenorhabditis elegans Parkinson's disease models via PMK-1/p38 MAPK and SKN-1/Nrf2 signaling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Cellular and systemic modifiers of alpha-synuclein proteostasis.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2026Review
- Dimethyl fumarate ameliorates quinolinic acid-induced ageing and neurodegeneration in Caenorhabditis elegans.Biogerontology · 2026Article
- Cycloneolitsol prolongs the lifespan of Caenorhabditis elegans by SEK-1/PMK-1/SKN-1 pathway and exerts anti-inflammatory effects by NF-κB pathway.Biogerontology · 2026Article
- Caenorhabditis elegans as an experimental model for resilience-boosting microbiota interventions in nonmodel ectotherms.FEMS microbiology reviews · 2026Review
- Ethyl Acetate Extract ofCurrent issues in molecular biology · 2025Article
- Leveraging open cheminformatics tools for non-targeted metabolomics analysis of C. elegans: a workflow comparison and application to strains related to xenobiotic metabolism and neurodegeneration.Analytical and bioanalytical chemistry · 2025Article
- Genome report of a probioticMicrobiology resource announcements · 2025Article
- Gut Microbiome as a Source of Probiotic Drugs for Parkinson's Disease.International journal of molecular sciences · 2025Review
- Childhood penetrating intracranial injury by non-metallic objects: a case report of three pediatric cases.Translational pediatrics · 2025Article
- A gut microbiota-based predictive model for the treatment efficacy of Parkinson's disease.Frontiers in neurology · 2025Article
- Lactic acid bacteria alleviate neuronal excitotoxicity and extendTurkish journal of biology = Turk biyoloji dergisi · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a no-curable neurodegenerative disease of pandemic distribution for which only palliative treatments are available. A hallmark of PD is injury to dopaminergic neurons in the substantia nigra pars compacta. Here, we report that Caenorhabditis elegans colonized by biofilm-forming Bacillus subtilis is resistant to injury of dopaminergic neurons caused by treatment with the PD-related neurotoxin 6-hydroxydopamine (6-OHDA). Biofilm-forming B. subtilis-colonized C. elegans display dopamine-dependent behaviors indistinguishable from those of 6-OHDA-untreated worms colonized by gut commensal E. coli OP50. In C. elegans PD model strains with early dopaminergic neuron decay or overexpressing human alpha-synuclein, biofilm-forming B. subtilis colonization had neuroprotective effects and prevents alpha-synulcein aggregation, respectively. The B. subtilis-controlled insulin/IGF-1 signaling (ILS), whose downregulation prevents aging-related PD, is not involved in protecting against 6-OHDA-related injury. We demonstrate that biofilm-forming B. subtilis activates PMK-1 (p38 MAPK)/SKN-1 (Nrf2) signaling, which protects C. elegans from 6-OHDA-induced dopaminergic neuron injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.